Key facts
- Surv BioPharma’s last known valuation is $32.5M (Dec 2025).
- It has raised $21.3M; the latest was Early Stage VC ($13.9M) in Dec 2025.
- Notable investors include Nippon Venture Capital, FFG Venture Business Partners, Keio Innovation Initiative, Kyoto University Innovation Capital, Sagin Capital & Consulting — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Surv BioPharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Surv BioPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Surv BioPharma
Developer of gene therapies designed to improve the treatment of various diseases. The company's platform utilizes drug delivery systems and targeted therapy approaches, aiming to enhance drug efficacy while minimizing side effects, enabling healthcare providers to offer more precise and effective treatments to patients in need of specialized medical care.
- Sector
- Healthcare
- HQ
- Kagoshima, Japan
- Founded
- 2022
- Employees
- 12
- Website
- survbiopharma.co.jp/
- Ownership
- Privately Held (backing)
Surv BioPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Surv BioPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Surv BioPharma in its N-PORT filings yet. We sweep new filings monthly.